Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H7N4O5.K |
Molecular Weight | 302.2847 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[K+].[O-][N+](=O)C1=CC=C(O1)\C=C\C=N\N2CC(=O)[N-]C2=O
InChI
InChIKey=ZKIAXFGFUSGPGQ-NGTWICJZSA-M
InChI=1S/C10H8N4O5.K/c15-8-6-13(10(16)12-8)11-5-1-2-7-3-4-9(19-7)14(17)18;/h1-5H,6H2,(H,12,15,16);/q;+1/p-1/b2-1+,11-5+;
Molecular Formula | K |
Molecular Weight | 39.0983 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C10H8N4O5 |
Molecular Weight | 264.1943 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Optical Activity | NONE |
Furagin (Furazidine) is a nitrofuran derivative, acting as an antibacterial medicine with bacteriostatic action. It is active against both gram-positive (Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus faecalis) and gram-negative microorganisms (Enterobacteriaceae – Salmonella, Shygella, Proteus, Klebsiella, Escherichia, Enterobacter, etc.). It is used for the treatment of urinary tract, skin and soft tissues infections.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Furagin Approved UseFuragin (Furazidine) is indicated for the treatment of urinary tract infections. Topical furagin is used in the treatment of infections of the skin and soft tissues. |
|||
Curative | Furagin Approved UseFuragin (Furazidine) is indicated for the treatment of urinary tract infections. Topical furagin is used in the treatment of infections of the skin and soft tissues. |
PubMed
Title | Date | PubMed |
---|---|---|
[Experimental studies on a new chemotherapeutic preparation furazidin]. | 1958 Jul |
|
Pharmacokinetics of furagin, a new nitrofurantoin congener, on human volunteers. | 1979 Jun |
|
Ciprofloxacin and furagin in acute cystitis: comparison of early immune and microbiological results. | 2008 Feb |
Sample Use Guides
Adults: 50-100 mg t.i.d., for 7-14 days.
0.5% or 1% solution for topical applications.
Route of Administration:
Other
In Vitro Use Guide
Sources: http://en.medicine-cure.com/ovr3_furamag.htm
Furagin (Furazidine) is a broad-spectrum antimicrobial agent belonging to the group of nitrofurans. Against the majority of bacteria, the bacteriostatic concentration ranges from 1: 100,000 to 1: 200,000; bactericidal - about 2 times more.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:12:25 UTC 2023
by
admin
on
Sat Dec 16 08:12:25 UTC 2023
|
Record UNII |
V2G0J52HRB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9577021
Created by
admin on Sat Dec 16 08:12:25 UTC 2023 , Edited by admin on Sat Dec 16 08:12:25 UTC 2023
|
PRIMARY | |||
|
58517-73-0
Created by
admin on Sat Dec 16 08:12:25 UTC 2023 , Edited by admin on Sat Dec 16 08:12:25 UTC 2023
|
SUPERSEDED | |||
|
V2G0J52HRB
Created by
admin on Sat Dec 16 08:12:25 UTC 2023 , Edited by admin on Sat Dec 16 08:12:25 UTC 2023
|
PRIMARY | |||
|
100000163640
Created by
admin on Sat Dec 16 08:12:25 UTC 2023 , Edited by admin on Sat Dec 16 08:12:25 UTC 2023
|
PRIMARY | |||
|
21287-44-5
Created by
admin on Sat Dec 16 08:12:25 UTC 2023 , Edited by admin on Sat Dec 16 08:12:25 UTC 2023
|
PRIMARY | |||
|
SUB178044
Created by
admin on Sat Dec 16 08:12:25 UTC 2023 , Edited by admin on Sat Dec 16 08:12:25 UTC 2023
|
PRIMARY | |||
|
22844-11-7
Created by
admin on Sat Dec 16 08:12:25 UTC 2023 , Edited by admin on Sat Dec 16 08:12:25 UTC 2023
|
SUPERSEDED | |||
|
28177-02-8
Created by
admin on Sat Dec 16 08:12:25 UTC 2023 , Edited by admin on Sat Dec 16 08:12:25 UTC 2023
|
SUPERSEDED | |||
|
SUB35197
Created by
admin on Sat Dec 16 08:12:25 UTC 2023 , Edited by admin on Sat Dec 16 08:12:25 UTC 2023
|
ALTERNATIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |